Breaking Finance News

Forward Pharma A S (NASDAQ:FWP) has been upgraded to Hold in a statement by BidaskClub earlier today.

BidaskClub has upgraded Forward Pharma A S (NASDAQ:FWP) to Hold in a statement released on Tuesday June 20, 2017.

Boasting a price of $20.65, Forward Pharma A S (NASDAQ:FWP) traded 1.64% higher on the day. With the last stock price close down -71.96% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Forward Pharma A S has recorded a 50-day average of $23.01 and a two hundred day average of $22.15. Volume of trade was up over the average, with 141,042 shares of FWP changing hands over the typical 88,519

Performance Chart

Forward Pharma A S (NASDAQ:FWP)

With a total market value of $0, Forward Pharma A S has with a one year low of $5.46 and a one year high of $33.00 .

Brief Synopsis About Forward Pharma A S (NASDAQ:FWP)

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company's clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis. The Company's DMF formulation, FP187, employs over two methods, which improves the release of DMF by reducing the peaks of monomethyl fumarate (MMF) in the bloodstream while maintaining overall DMF exposure levels, which, in turn, controls DMF's side effects. The Company has conducted a pre-clinical program and has completed several Phase I and Phase II clinical trials for the product FP187.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.